Theralase Technologies Inc. V.TLT

Curious as to how the trial changes affect posted results !

[Oden6570]

With the new option to treat patients at any time ( 2 additional treatments if required ) will the numbers be in flux somewhat ?
For patients who have achieved a CR or IR at any point in time and have demonstrated a duration of that CR or IR, no further maintenance Study II Treatments would be administered; however, if the patient recurs at any scheduled assessment visit (i.e.: 90, 180, 270, 360 or 450 days), then that patient would be eligible to receive up to 2 maintenance Study II Treatments at the discretion of the PI to assist the patient in achieving a CR. 3) Central Pathology Laboratory Review - Use of a central pathology laboratory to validate local pathology laboratory results. Note: CR is defined as: Negative cystoscopy and negative (including atypical) urine cytology, Positive cystoscopy with biopsy-proven benign or low-grade NMIBC and negative cytology and Negative cystoscopy with malignant urine cytology, if urothelial cancer is suspected in the upper tract or prostatic urethra and rand adder biopsies are negative.
Theralase® Technologies Inc. Announces That It Has Been Granted Clinical Trial Application Amendment by Health Canada Through Receipt of A No Objection Letter for the Optimization of the Phase Ii Non-Muscle Invasive Bladder Cancer Clinical Study - MarketScreener